GlassMedical AI

About the Company

GlassMedical AI is a tech-bio platform developing predictive, explainable artificial intelligence models for oncology. The company operates within the biopharmaceutical and medical technology sector, focusing on supporting the development of cancer therapies. Its goal is to accelerate the development of effective cancer therapies and streamline the approval process through smarter and more precise clinical trials.

GlassMedical AI was established as a tech-bio spin-off, based on years of academic research in oncology and advanced data analytics, utilizing artificial intelligence methods to process complex biomedical data.

Technology and Solutions

GlassMedical AI develops predictive AI pipelines that support the development of oncology drugs and improve patient selection for clinical trials. The platform utilizes multimodal, explainable AI models that analyze various types of data (e.g., clinical and biomarker data), enabling more accurate predictions of therapy responses and study designs.

Key features of the technology include:

• Rapid patient stratification – supporting the division of patients into appropriate research groups based on clinical characteristics and biomarkers.
• Biomarker-driven trial design – designing clinical trials focused on specific biomarkers, which helps increase the effectiveness and safety of tested therapies.
• Explainable AI models – using algorithms whose operations can be interpreted, which is crucial for clinical and regulatory teams working on oncology drugs.

GlassMedical AI's technology is applicable across a wide range of oncology indications, including the development of novel therapies such as checkpoint inhibitors, CAR-T therapies, or TIL, helping to reach the appropriate patient groups more quickly and accurately.

Mission and Approach

The mission of GlassMedical AI is to accelerate the development of effective cancer therapies by enabling smarter, more precise clinical trials. The company aims to ensure that the right therapy reaches the right patient faster and in a data-driven manner.

GlassMedical AI emphasizes the combination of world-class AI with deep medical expertise, allowing technological innovations to translate into real improvements in treatment outcomes for patients with cancer. The team focuses on reducing the risk of oncology drug development and more efficiently managing the portfolio of therapies in clinical trials.

Services

GlassMedical AI offers solutions for entities developing oncology therapies, particularly:

• Predictive AI pipelines supporting the development and optimization of clinical trials in oncology.
• Patient stratification models that assist in selecting patients for trials based on clinical characteristics and biomarkers.
• Bespoke AI models, designed in collaboration with clinical and scientific experts (KOL – key opinion leaders), tailored to the specifics of a given therapy and patient population.

These solutions support:

• the design of better-targeted clinical trials,
• potential shortening of drug development time,
• reduction of failure risks in later phases of trials,
• transitioning from traditional trial management to more precision execution, i.e., precise execution of studies based on data and predictive models.

Target Audience

GlassMedical AI directs its services primarily to:

• pharmaceutical companies developing oncology drugs,
• biotechnology companies working on innovative cancer therapies,
• organizations conducting clinical trials in oncology that wish to improve patient selection and the effectiveness of research projects.

The platform is particularly valuable for teams:

• involved in clinical trial design,
• responsible for oncology drug portfolio development strategy,
• working on precision therapies and immunotherapies, where accurate patient selection is crucial for therapy effectiveness.

Location and Market Context

GlassMedical AI is present, among others, in Basel (Basel, Switzerland), an important center for the pharmaceutical and biotechnology sector, which facilitates collaboration with global companies and institutions operating in the health sector. The company operates at the intersection of biotechnology, pharmacy, and advanced data analysis, fitting into the growing trend of utilizing artificial intelligence in the design and conduct of clinical trials in oncology.

Value for Partners

By employing multimodal, explainable AI models, GlassMedical AI helps partners:

• optimize patient stratification in clinical trials,
• increase the chances of success for oncology drug development projects,
• deliver breakthrough therapies to patients who can benefit from them the most, more quickly.

By combining clinical data, biomarkers, and expert knowledge, GlassMedical AI's solutions support evidence-based decision-making, aiding both therapeutic innovations and improving treatment outcomes for cancer patients.

check

Old data replaced by AI research (2026-06-27) — verify and remove after checking.

• WWW (old): https://vonloga.ch
• Country (old): DE